Dare Bioscience, Inc. (DARE)

In Q3 2025, Daré Bioscience reported $23.1 million in cash and cash equivalents. The company highlighted its commercial launch readiness for DARE to PLAY™ Sildenafil Cream, with initial prescription fulfillment expected in December 2025. Bayer HealthCare LLC returned all rights to Ovaprene to Daré Bioscience. Daré Bioscience received approximately $3.6 million in funding under an existing grant. The company announced the initial closing of its Regulation A offering, issuing 5,090 units. In Q2 2025, the company reported $5.0 million in cash and equivalents. Positive interim results from the Ovaprene Phase 3 study were reported. The stock price gained 0.595% on February 6, 2026. Analysts anticipate the company to incur a final loss in 2026 before generating positive profits in 2027.

There is no explicit indication of demand seasonality for Daré Bioscience's products and services. Demand is primarily driven by ongoing medical needs and product availability rather than seasonal fluctuations.

Daré Bioscience, Inc. is a clinical-stage biopharmaceutical company focused on advancing products for women's health, addressing unmet needs in areas such as contraception, sexual health, and menopause. Its product portfolio includes XACIATO™ (clindamycin phosphate) vaginal gel 2%, Ovaprene®, DARE to PLAY™ Sildenafil Cream, 3.6%, DARE-HRT1, DARE-VVA1, DARE-HPV, DARE-PDM1, DARE-204 and DARE-214, DARE-FRT1, DARE-PTB1 and DARE-PTB2, DARE-LARC1, DARE-LBT, DARE-GML, and DARE to RESTORE™ Vaginal Probiotics.

Daré Bioscience, Inc. is headquartered in San Diego, California, and primarily focuses its commercialization efforts within the United States.

Daré Bioscience maintains a positive brand reputation due to its mission to address unmet needs in women's health. The company is recognized for its science-driven and patient-centric approach. Daré Bioscience leadership has been acknowledged on prestigious lists, and its CEO was honored as one of Fierce Pharma's Most Influential People in Biopharma.

Daré Bioscience, Inc. has 24 institutional owners and shareholders. Institutional Investors own approximately 2.90% to 5.15% of the company's stock, Insiders own 7.44%, and Public Companies and Individual Investors own a significant portion (87.40% or 83.2%). Major institutional shareholders include Vanguard Group Inc., VTSMX, AMH Equity Ltd., Geode Capital Management, Llc., VEXMX, Susquehanna International Group, Llp., Renaissance Technologies Llc., State Street Corp., US Bancorp \de, UBS Group AG, and Law Custodial, Inc. Sabrina Johnson, the President and CEO, is also a notable individual owner.